Schering-Plough’s Intron A gets EU label change
The large five-year study confirms that sustained loss of serum hepatitis C virus (HCV) RNA six months following the completion of treatment with nonpegylated interferon alfa-2b (with or
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).